vs
ACME UNITED CORP（ACU）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
ACME UNITED CORP的季度营收约是REGENXBIO Inc.的1.7倍（$52.3M vs $30.3M），ACME UNITED CORP净利率更高（1.9% vs -221.3%，领先223.2%），REGENXBIO Inc.同比增速更快（43.0% vs 13.8%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -2.9%）
埃克米联合公司（Acme United Corporation）是面向校园、家居、办公、五金及工业领域的切削工具、测量工具与安全防护用品供应商，行业历史悠久，其前身可追溯至1867年成立的合伙企业，1873年在康涅狄格州完成法人注册，目前在美国纽约泛欧美交所挂牌上市，股票代码为ACU。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
ACU vs RGNX — 直观对比
营收规模更大
ACU
是对方的1.7倍
$30.3M
营收增速更快
RGNX
高出29.2%
13.8%
净利率更高
ACU
高出223.2%
-221.3%
两年增速更快
RGNX
近两年复合增速
-2.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $52.3M | $30.3M |
| 净利润 | $985.0K | $-67.1M |
| 毛利率 | 39.7% | — |
| 营业利润率 | 3.3% | -190.0% |
| 净利率 | 1.9% | -221.3% |
| 营收同比 | 13.8% | 43.0% |
| 净利润同比 | -40.4% | -31.2% |
| 每股收益（稀释后） | $0.24 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACURGNX
| Q1 26 | $52.3M | — | ||
| Q4 25 | $47.5M | $30.3M | ||
| Q3 25 | $49.1M | $29.7M | ||
| Q2 25 | $54.0M | $21.4M | ||
| Q1 25 | $46.0M | $89.0M | ||
| Q4 24 | $45.9M | $21.2M | ||
| Q3 24 | $48.2M | $24.2M | ||
| Q2 24 | $55.4M | $22.3M |
净利润ACURGNX
| Q1 26 | $985.0K | — | ||
| Q4 25 | $1.9M | $-67.1M | ||
| Q3 25 | $1.9M | $-61.9M | ||
| Q2 25 | $4.8M | $-70.9M | ||
| Q1 25 | $1.7M | $6.1M | ||
| Q4 24 | $1.7M | $-51.2M | ||
| Q3 24 | $2.2M | $-59.6M | ||
| Q2 24 | $4.5M | $-53.0M |
毛利率ACURGNX
| Q1 26 | 39.7% | — | ||
| Q4 25 | 38.2% | — | ||
| Q3 25 | 39.1% | — | ||
| Q2 25 | 41.0% | — | ||
| Q1 25 | 39.0% | — | ||
| Q4 24 | 38.7% | 70.2% | ||
| Q3 24 | 38.5% | 48.8% | ||
| Q2 24 | 40.8% | 52.5% |
营业利润率ACURGNX
| Q1 26 | 3.3% | — | ||
| Q4 25 | 6.1% | -190.0% | ||
| Q3 25 | 6.1% | -176.3% | ||
| Q2 25 | 11.8% | -296.3% | ||
| Q1 25 | 5.3% | 13.6% | ||
| Q4 24 | 5.0% | -242.1% | ||
| Q3 24 | 6.1% | -256.6% | ||
| Q2 24 | 11.5% | -251.3% |
净利率ACURGNX
| Q1 26 | 1.9% | — | ||
| Q4 25 | 3.9% | -221.3% | ||
| Q3 25 | 3.9% | -208.3% | ||
| Q2 25 | 8.8% | -331.8% | ||
| Q1 25 | 3.6% | 6.8% | ||
| Q4 24 | 3.7% | -241.3% | ||
| Q3 24 | 4.6% | -246.3% | ||
| Q2 24 | 8.0% | -237.7% |
每股收益（稀释后）ACURGNX
| Q1 26 | $0.24 | — | ||
| Q4 25 | $0.46 | $-1.30 | ||
| Q3 25 | $0.46 | $-1.20 | ||
| Q2 25 | $1.16 | $-1.38 | ||
| Q1 25 | $0.41 | $0.12 | ||
| Q4 24 | $0.43 | $-0.99 | ||
| Q3 24 | $0.54 | $-1.17 | ||
| Q2 24 | $1.09 | $-1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $4.2M | $230.1M |
| 总债务越低越好 | $33.0M | — |
| 股东权益账面价值 | $116.7M | $102.7M |
| 总资产 | $195.2M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.28× | — |
8季度趋势，按日历期对齐
现金及短期投资ACURGNX
| Q1 26 | $4.2M | — | ||
| Q4 25 | $3.6M | $230.1M | ||
| Q3 25 | $5.1M | $274.2M | ||
| Q2 25 | $3.6M | $323.3M | ||
| Q1 25 | $3.4M | $267.9M | ||
| Q4 24 | $6.4M | $234.7M | ||
| Q3 24 | $5.7M | $255.5M | ||
| Q2 24 | $3.8M | $290.4M |
总债务ACURGNX
| Q1 26 | $33.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益ACURGNX
| Q1 26 | $116.7M | — | ||
| Q4 25 | $117.6M | $102.7M | ||
| Q3 25 | $115.8M | $161.5M | ||
| Q2 25 | $113.7M | $213.7M | ||
| Q1 25 | $108.3M | $274.2M | ||
| Q4 24 | $107.0M | $259.7M | ||
| Q3 24 | $106.3M | $301.4M | ||
| Q2 24 | $104.0M | $348.3M |
总资产ACURGNX
| Q1 26 | $195.2M | — | ||
| Q4 25 | $171.0M | $453.0M | ||
| Q3 25 | $173.0M | $525.2M | ||
| Q2 25 | $170.9M | $581.0M | ||
| Q1 25 | $163.0M | $490.9M | ||
| Q4 24 | $162.2M | $466.0M | ||
| Q3 24 | $165.5M | $519.1M | ||
| Q2 24 | $173.5M | $569.4M |
负债/权益比ACURGNX
| Q1 26 | 0.28× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流ACURGNX
| Q1 26 | — | — | ||
| Q4 25 | $8.2M | $-52.3M | ||
| Q3 25 | $7.1M | $-56.0M | ||
| Q2 25 | $6.3M | $-49.3M | ||
| Q1 25 | $-3.3M | $33.6M | ||
| Q4 24 | $6.4M | $-31.6M | ||
| Q3 24 | $8.9M | $-40.5M | ||
| Q2 24 | $6.9M | $-45.5M |
自由现金流ACURGNX
| Q1 26 | — | — | ||
| Q4 25 | $7.3M | $-52.8M | ||
| Q3 25 | $301.0K | $-56.5M | ||
| Q2 25 | $4.7M | $-49.7M | ||
| Q1 25 | $-4.7M | $32.6M | ||
| Q4 24 | $4.7M | $-32.7M | ||
| Q3 24 | $7.5M | $-40.9M | ||
| Q2 24 | $4.4M | $-46.0M |
自由现金流率ACURGNX
| Q1 26 | — | — | ||
| Q4 25 | 15.3% | -174.0% | ||
| Q3 25 | 0.6% | -189.9% | ||
| Q2 25 | 8.7% | -232.8% | ||
| Q1 25 | -10.2% | 36.6% | ||
| Q4 24 | 10.2% | -154.2% | ||
| Q3 24 | 15.6% | -168.9% | ||
| Q2 24 | 8.0% | -206.2% |
资本支出强度ACURGNX
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 1.7% | ||
| Q3 25 | 13.8% | 1.7% | ||
| Q2 25 | 3.0% | 1.8% | ||
| Q1 25 | 2.9% | 1.2% | ||
| Q4 24 | 3.7% | 5.1% | ||
| Q3 24 | 2.8% | 1.3% | ||
| Q2 24 | 4.5% | 2.1% |
现金转化率ACURGNX
| Q1 26 | — | — | ||
| Q4 25 | 4.34× | — | ||
| Q3 25 | 3.72× | — | ||
| Q2 25 | 1.33× | — | ||
| Q1 25 | -2.02× | 5.53× | ||
| Q4 24 | 3.73× | — | ||
| Q3 24 | 3.99× | — | ||
| Q2 24 | 1.55× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACU
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
